George Vassilopoulos

Dr. George Vassilopoulos

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2009 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
Vasiliki MollakiVasiliki Mollaki
Vasiliki Mollaki
TGThomas Georgiadis
Thomas Georgiadis
ATAnna Tassidou
Anna Tassidou
MIMaria Ioannou
Maria Ioannou
ZDZoe Daniil
Zoe Daniil
GVGeorge Vassilopoulos
George Vassilopoulos
Toll-like receptors (TLRs) and myeloid differentiation primary response protein 88 (MYD88) gene polymorphisms may be involved in the pathogenesis of Hodgkin's lymphoma (HL) through altered immunoregulatory and inflammatory responses. A candidate–gene association study was conducted to investigate the association between TLR9 −1237T>C, TLR9 2848A>G, MYD88 −938C>A and MYD88 1944C>G gene polymorphisms and the risk for HL. The impact of haplotypes was also examined. The study showed that carriership for −1237C and 2848A was associated with an increased risk for HL (odds ratio (OR)=2.53 (1.36–4.71) and OR=6.20 (1.3–28.8)). The MYD88 polymorphisms produced nonsignificant results. The estimated frequencies of the TLR9/1237C-2848A and MYD88/938C-1944G haplotypes were also significantly different between HL and controls (P<0.01). In addition, a significant difference between HL and controls was observed for the TLR9/1237C-TLR9/2848A-MYD88/938C-MYD88/1944C haplotypes (P<0.01). In conclusion, our study showed that TLR polymorphisms, and TLR9 and MYD88 haplotypes are related to the development of HL.

1 February 2019 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
ECEvangelia-Eleni Christaki
Evangelia-Eleni Christaki
MPMarianna Politou
Marianna Politou
MAMarianna Antonelou
Marianna Antonelou
AAAngelos Athanasopoulos
Angelos Athanasopoulos
ESEmmanouil Simantirakis
Emmanouil Simantirakis
GVGeorge Vassilopoulos
George Vassilopoulos

19 January 2024 in Life
Verified
Journal Article
Open access
PDF file
ABAngeliki Bourazana
Angeliki Bourazana
Andrew XanthopoulosAndrew Xanthopoulos
Andrew Xanthopoulos
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
Dimitrios E. MagouliotisDimitrios E. Magouliotis
Dimitrios E. Magouliotis
KSKyriakos Spiliopoulos
Kyriakos Spiliopoulos
FTFilippos Triposkiadis
Filippos Triposkiadis
In recent times, there have been notable changes in cardiovascular medicine, propelled by the swift advancements in artificial intelligence (AI). The present work provides an overview of the current applications and challenges of AI in the field of heart failure. It emphasizes the “garbage in, garbage out” issue, where AI systems can produce inaccurate results with skewed data. The discussion covers issues in heart failure diagnostic algorithms, particularly discrepancies between existing models. Concerns about the reliance on the left ventricular ejection fraction (LVEF) for classification and treatment are highlighted, showcasing differences in current scientific perceptions. This review also delves into challenges in implementing AI, including variable considerations and biases in training data. It underscores the limitations of current AI models in real-world scenarios and the difficulty in interpreting their predictions, contributing to limited physician trust in AI-based models. The overarching suggestion is that AI can be a valuable tool in clinicians’ hands for treating heart failure patients, as far as existing medical inaccuracies have been addressed before integrating AI into these frameworks.

11 May 2013 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ZDZ. Daniil
Z. Daniil
Vasiliki MollakiVasiliki Mollaki
Vasiliki Mollaki
FMF. Malli
F. Malli
AKAngela Koutsokera
Angela Koutsokera
KAK. M. Antoniou
K. M. Antoniou
GVGeorge Vassilopoulos
George Vassilopoulos

1 May 1991 in Blood
Verified
Journal Article
Open access
PDF file
GLG Loudianos
G Loudianos
ACA Cao
A Cao
MPM Pirastu
M Pirastu
GVGeorge Vassilopoulos
George Vassilopoulos
PKP Kollia
P Kollia
DLD Loukopoulos
D Loukopoulos

19 March 2020 in Viruses
Verified
Journal Article
Open access
PDF file
ESEmmanouil Simantirakis
Emmanouil Simantirakis
ITIoannis Tsironis
Ioannis Tsironis
GVGeorge Vassilopoulos
George Vassilopoulos
Hematopoietic Stem Cells (HSCs) are a unique population of cells, capable of reconstituting the blood system of an organism through orchestrated self-renewal and differentiation. They play a pivotal role in stem cell therapies, both autologous and allogeneic. In the field of gene and cell therapy, HSCs, genetically modified or otherwise, are used to alleviate or correct a genetic defect. In this concise review, we discuss the use of SFVpsc_huHSRV.13, formerly known as Prototype Foamy Viral (PFV or FV) vectors, as vehicles for gene delivery in HSCs. We present the properties of the FV vectors that make them ideal for HSC delivery vehicles, we review their record in HSC gene marking studies and their potential as therapeutic vectors for monogenic disorders in preclinical animal models. FVs are a safe and efficient tool for delivering genes in HSCs compared to other retroviral gene delivery systems. Novel technological advancements in their production and purification in closed systems, have allowed their production under cGMP compliant conditions. It may only be a matter of time before they find their way into the clinic.